The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
An Association between Reduced Susceptibility to Daptomycin and Reduced Susceptibility to Vancomycin in Staphylococcus aureus
Abstract
To THE EDITOR—Daptomycin, a novel lipopeptide antimicrobial agent, is being used with increasing frequency for managing infections caused by drug-resistant, gram-positive bacteria with reduced susceptibility to vancomycin (including Staphylococcus aureus) [1]. Daptomycin has a unique mechanism of action, which includes Ca2+-dependent insertion of the agent into bacterial cytoplasmic membranes. Because the mechanism of action is unique, it was predicted that daptomycin would not exhibit cross-resistance with other antimicrobial agents. However, it appears that S. aureus with reduced susceptibility to vancomycin (i.e., isolates for which the vancomycin MICs are 4–16 µg/mL) also exhibit reduced susceptibility to daptomycin. This was initially described by Jevitt et al. [2], who reported a daptomycin MIC50 of 2 µg/mL and an MIC90 of 8 µg/mL for 19 isolates of S. aureus for which the vancomycin MICs were 4 µg/mL (16 isolates) or 8 µg/mL (3 isolates). S. aureus with daptomycin MICs of ⩽1 µg/mL are considered to be susceptible according to the Clinical and Laboratory Standards Institute [3]. In reviewing results for a larger number of independent S. aureus isolates submitted to the Centers for Disease Control and Prevention for antimicrobial susceptibility testing, we noted an association between a vancomycin MIC of 4 µg/mL or 8 µg/mL and a daptomycin MIC of ⩾2 µg/mL (P < .0001; χ2 test for trend) (table 1). Exceptions to this include glycopeptide intermediate S. aureus–992, a vancomycin-intermediate S. aureus isolate from New Jersey reported by Akins et al. [4], for which the vancomycin MIC was 8 µg/mL and the daptomycin MIC was 1 µg/mL. Results of susceptibility tests performed at the Centers for Disease Control and Prevention are consistent with those results. However, for the majority of other S. aureus isolates from the United States for which the vancomycin MICs are 4–16 µg/mL, the daptomycin MICs were ⩾2 µg/mL (i.e., nonsusceptible). Effect of increasing vancomycin MICs on daptomycin susceptibility for Staphylococcus aureus isolates. It is conceivable that the changes mediating reduced susceptibility to vancomycin in S. aureus, including a thickened cell wall, changes in cellular metabolism, and enhanced cell wall turnover, interfere with the antimicrobial action of daptomycin [5, 6]. However, the 5 vancomycin-resistant S. aureus isolates (MICs ⩾32 µg/mL) reported in the United States that contain the vanA resistance determinant [7–9, unpublished data] have all been susceptible to daptomycin (MICs ⩽1 µg/mL). Thus, vanA-mediated resistance does not appear to affect daptomycin susceptibility. On the basis of these observations, we suggest that clinicians exercise caution when considering daptomycin for treatment of an S. aureus infection when reduced susceptibility to vancomycin is suspected or documented. In such cases, the S. aureus isolate should be tested for susceptibility to daptomycin by either a broth microdilution or gradient diffusion method (e.g., Etest; AB Biodisk) prior to initiating therapy. Potential conflicts of interest. All authors: no conflicts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025025 · Cited by 1,095
Self-citation
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609839104 · Cited by 538
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
French, G. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl393 · Cited by 441
Methicillin-Resistant Staphylococcus aureus: An Evolving Pathogen
Stryjewski, M. E., & Corey, G. R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit613 · Cited by 334
Metadata
- Authors
- Patel, J. B., Jevitt, L. A., Hageman, J., McDonald, L. C., & Tenover, F. C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06-01
- Volume
- 42
- Issue
- 11
- Pages
- 1652-1653
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2041975350
- Cited by
- 183
- References
- 1
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Association between Reduced Susceptibility to Daptomycin and Reduced Susceptibility to Vancomycin in Staphylococcus aureus. https://app.cochat.ai/papers/10.1086/504084
- The paper
- Patel, J. B., Jevitt, L. A., Hageman, J., McDonald, L. C., & Tenover, F. C. (2006). An Association between Reduced Susceptibility to Daptomycin and Reduced Susceptibility to Vancomycin in Staphylococcus aureus. Clinical Infectious Diseases. https://doi.org/10.1086/504084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.